CN-121987606-A - Application of alpha-hydroxy isocaproic acid-containing nutritional composition in weight management and blood fat improvement

Abstract

The invention discloses an application of an alpha-hydroxy isocaproic acid-containing nutritional composition in weight management and blood fat improvement, belonging to the fields of biological medicine manufacturing, biological medical application and functional food development. The nutritional composition comprises alpha-hydroxy isohexide and at least one second functional nutritional component, preferably any one or more of 1) one or more of tea polyphenols, capsaicin, 2) one or more of beta-glucan, inulin, resistant dextrin, 3) one or more of medium chain triglycerides, sn-1,3 diglycerides, 4) one or more of omega-3 fatty acid source oils, phytosterols. Under the condition of the same intake period and dosage, the nutritional composition can obviously improve the weight management effect and reduce the blood fat related index through the multi-way synergistic effect. Combined with GLP-1 drugs or sequentially applied to weight management so as to reduce the risk of weight regain after drug withdrawal.

Inventors

• HU JIANGNING
• CHEN TAO

Assignees

• 大连工业大学

Dates

Publication Date

20260508

Application Date

20260310

Claims (10)

1. 1. An alpha-hydroxyisocaproic acid-containing nutritional composition characterized by comprising alpha-hydroxyisocaproic acid and at least one second functional nutritional component; the second functional nutritional component is preferably any one or more of the following: 1) One or more of tea polyphenols and capsaicin; 2) One or more of beta-glucan, inulin, resistant dextrin; 3) One or more of medium chain triglycerides, sn-1,3 diglycerides; 4) Omega-3 fatty acid-derived oils and fats, and phytosterols.
2. 2. The alpha-hydroxyisocaproic acid-containing nutritional composition according to claim 1, wherein the mass ratio of alpha-hydroxyisocaproic acid to the second functional nutritional component is 1:10-5:1.
3. 3. The alpha-hydroxyisohexanoic acid-containing nutritional composition according to claim 1, wherein the mass ratio of alpha-hydroxyisohexanoic acid to the second functional nutritional component is 1:1-5:1 when the second functional nutritional component is capsaicin, 1:10-1:1 when the second functional nutritional component is one or more of beta-glucan, inulin, and resistant dextrin, and 1:10-1:1 when the second functional nutritional component is one or more of medium chain triglycerides, sn-1,3 diglycerides.
4. 4. The alpha-hydroxyisohexanoic acid containing nutritional composition according to claim 1, further comprising a nutritional matrix selected from one or more of proteins, carbohydrates, lipids, dietary fibers, vitamins, minerals; wherein the lipid or dietary fiber does not comprise the second functional nutritional component, and the protein is selected from one or more of whey protein, casein, soy protein, pea protein and collagen peptide.
5. 5. The alpha-hydroxyisohexanoic acid containing nutritional composition according to claim 1, further comprising food grade excipients and/or delivery systems comprising emulsions and/or nanoemulsions; The product form of the alpha-hydroxy isocaproic acid-containing nutritional composition is powder, granule, tablet, capsule, oral liquid, beverage, milk beverage or gel form.
6. 6. The alpha-hydroxyisocaproic acid-containing nutritional composition according to claim 1, wherein the content of alpha-hydroxyisocaproic acid in the nutritional composition is such that the daily intake of the adult is in the range of 0.1-2.0 g/d, preferably 1.5 g/d, most preferably 0.5 g/time, 3 times daily.
7. 7. Use of the alpha-hydroxy isocaproic acid-containing nutritional composition according to claim 1 for the preparation of weight management, blood lipid improving food, health care products, special medical food.
8. 8. Use according to claim 7, in combination with GLP-1 based drugs, of an alpha-hydroxyisohexide-containing nutritional composition for weight maintenance after weight loss.
9. 9. The use according to claim 8, wherein the GLP-1 drug is administered alone, and the administration of the alpha-hydroxyisocaproic acid-containing nutritional composition for weight maintenance is continued after stopping the GLP-1 drug after weight loss to the desired target, or the intake is gradually reduced or even stopped after weight maintenance; At the end of the observation period, which is 2-12 weeks after cessation of GLP-1-based drug, the subject's body weight is increased by no more than 70%, preferably no more than 50%, more preferably no more than 30% of the body weight decrease during the GLP-1-based drug treatment period relative to the body weight at the time of cessation of GLP-1-based drug administration.
10. 10. The use according to claim 8, wherein the GLP-1 class of drug is a GLP-1 receptor agonist and/or a drug comprising GLP-1 receptor agonistic activity, selected from the group consisting of semaglutin, liraglutide, telipopeptide, duloxetide, exenatide, risinaide, abirudin or a pharmaceutically acceptable salt, prodrug, solvate or crystalline form thereof.

Description

Application of alpha-hydroxy isocaproic acid-containing nutritional composition in weight management and blood fat improvement Technical Field The invention relates to the fields of biological medicine manufacture, biological medical application and functional food development, in particular to application of an alpha-hydroxy isocaproic acid-containing nutritional composition in weight management and blood fat improvement. Background With global lifestyle changes, overweight, obesity and concomitant dyslipidemia (hypertriglyceridemia, hypercholesterolemia, etc.) have become central risk factors for the induction of cardiovascular disease, type II diabetes, and nonalcoholic fatty liver disease. The existing clinical intervention and nutrition management means are various, but still face significant technical bottlenecks and application limitations, namely 1) the limitations of the existing pharmaceutical intervention and side effects the currently mainstream weight-reducing drugs (such as GLP-1 receptor agonists and the like) mainly act on the central nervous system or the digestive tract to generate a strong appetite suppression effect. However, this "appetite-blocking" pathway is often accompanied by significant gastrointestinal adverse effects (e.g., nausea, vomiting, risk of ileus) and often results in non-selective weight loss, including significant skeletal muscle loss. In addition, such drugs generally face extremely high weight rebound rates after withdrawal, and it is difficult to achieve long-term maintenance of metabolic homeostasis. 2) Metabolic compensation effects of single nutritional pathways conventional functional nutrients (such as single tea polyphenols, capsaicin or dietary fiber, etc.) tend to be directed only to a specific node of lipid metabolism (such as thermogenesis or physical blocking of absorption). Because the organism metabolism regulation and control has extremely strong compensatory property, the intervention of a single path is easily counteracted by the organism through feedback mechanisms such as down-regulating basic metabolism or up-regulating lipid intake, so that the intervention effect shows larger fluctuation in people with different diet backgrounds, and the comprehensive improvement of body fat reduction and blood fat indexes is difficult to realize at the same time. The body weight management and dyslipidemia formation mechanism is complex, and single active ingredients are difficult to cover key links such as energy consumption/heat production, lipid absorption/discharge, fat oxidation/lipolysis, lipoprotein metabolism and the like at the same time, so that the problems of insufficient effect consistency, fluctuation in maintenance period and the like can occur in different dietary structures and metabolic background people. Furthermore, the current studies put different conclusions on HIC-related metabolic effects, including reports on promotion of lipid absorption, fat deposition, suggest that intervention strategies relying on only a single component still have room for further optimization in terms of applicable boundaries, intervention intensity and long-term stability. Therefore, there is a need to provide new active ingredients and/or combination strategies for weight management and improving blood lipid index on the one hand, and on the other hand, to be able to complement GLP-1 class drugs, achieving weight maintenance, reducing rebound after disabling GLP-1 class drugs. Disclosure of Invention In order to solve the problems in the prior art, the application of the nutritional composition containing the alpha-hydroxy isocaproic acid in weight management and blood fat improvement is provided. The nutritional composition comprises HIC and further comprises at least one second functional nutritional component, thereby constructing a multi-path complementary nutritional intervention regimen for weight management and/or improving blood lipid related indicators. Alpha-hydroxyisocaproic acid (2-Hydroxyisocaproic acid, HIC) is a small molecular compound naturally occurring in a variety of fermented foods, such as certain cheeses, soy sauce, wine, etc., and therefore it has a safety basis as a dietary source. The technical scheme of the invention is as follows: It is an object of the present invention to provide an alpha-hydroxyisocaproic acid comprising alpha-hydroxyisocaproic acid (HIC) and at least one second functional nutritional component; the second functional nutritional component is preferably any one or more of the following: 1) One or more of tea polyphenols and capsaicin, and can promote energy consumption or heat generation; 2) One or more of beta-glucan, inulin and resistant dextrin, which can inhibit lipid absorption or promote lipid excretion; 3) One or more of Medium Chain Triglycerides (MCT), sn-1,3 Diglycerides (DAG), which promote fat oxidation or lipolysis; 4) Omega-3 fatty acid source oil and/or plant sterol, and improving blood lipid index